Share-based Payment Arrangement, Expense of Crinetics Pharmaceuticals, Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Crinetics Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Crinetics Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $22,702,000, a 25% increase year-over-year.
  • Crinetics Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $88,149,000, a 42% increase year-over-year.
  • Crinetics Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $69,386,000, a 69% increase from 2023.
  • Crinetics Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $40,937,000, a 45% increase from 2022.
  • Crinetics Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $28,268,000, a 63% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Crinetics Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $88,149,000 $22,702,000 +$4,555,000 +25% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $83,594,000 $26,124,000 +$7,184,000 +38% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $76,410,000 $20,478,000 +$7,024,000 +52% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $69,386,000 $18,845,000 +$7,228,000 +62% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $62,158,000 $18,147,000 +$7,098,000 +64% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $55,060,000 $18,940,000 +$8,765,000 +86% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $46,295,000 $13,454,000 +$5,358,000 +66% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $40,937,000 $11,617,000 +$3,669,000 +46% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $37,268,000 $11,049,000 +$3,615,000 +49% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $33,653,000 $10,175,000 +$3,044,000 +43% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $30,609,000 $8,096,000 +$2,341,000 +41% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $28,268,000 $7,948,000 +$2,790,000 +54% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $25,478,000 $7,434,000 +$2,879,000 +63% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $22,599,000 $7,131,000 +$2,898,000 +68% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $19,701,000 $5,755,000 +$2,349,000 +69% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $17,352,000 $5,158,000 +$2,188,000 +74% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $15,164,000 $4,555,000 +$1,773,000 +64% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $13,391,000 $4,233,000 +$1,705,000 +67% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $11,686,000 $3,406,000 +$1,259,000 +59% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $10,427,000 $2,970,000 +$1,139,000 +62% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $9,288,000 $2,782,000 +$928,000 +50% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $8,360,000 $2,528,000 +$947,000 +60% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $7,413,000 $2,147,000 +$1,119,000 +109% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $6,294,000 $1,831,000 +$983,000 +116% 01 Oct 2019 31 Dec 2019 10-K 30 Mar 2022 2021 FY
Q3 2019 $5,311,000 $1,854,000 +$1,079,000 +139% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $4,232,000 $1,581,000 +$1,310,000 +483% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $2,922,000 $1,028,000 +$602,000 +141% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $2,320,000 $848,000 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2021 2020 FY
Q3 2018 $775,000 +$705,000 +1007% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $271,000 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2
Q1 2018 $426,000 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1
Q3 2017 $70,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3

Crinetics Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $69,386,000 +$28,449,000 +69% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $40,937,000 +$12,669,000 +45% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $28,268,000 +$10,916,000 +63% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $17,352,000 +$6,925,000 +66% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $10,427,000 +$4,133,000 +66% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $6,294,000 +$3,974,000 +171% 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2022 2021 FY
2018 $2,320,000 +$2,049,000 +756% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2021 2020 FY
2017 $271,000 +$1,000 +0.37% 01 Jan 2017 31 Dec 2017 10-K 09 Mar 2020 2019 FY
2016 $270,000 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.